FDA Approves Pfizer's Braftovi Plus Cetuximab for Colorectal Cancer with BRAF Mutations

[cafead]

via The U.S. Food and Drug Administration (FDA) approved Pfizer’s Braftovi (encorafenib) in combination with cetuximab (Erbitux) for adults with metastatic colorectal cancer (CRC) with a BRAFV600E mutation. The mutation is identified with an FDA-approved companion diagnostic, and the indication is for after previous therapy.

article source